52 Week Range
As of on the NASDAQ ∙ Minimum 15 minute delay
3M AVG Volume
52 Week High
52 Week Low
Shares Out (MIL)
Market Cap (MIL)
Dividend (Yield %)
Catalyst Pharmaceuticals Posts Q1 EPS Of $0.07
Catalyst Pharmaceuticals Announces $40 Mln Share Repurchase Program
Catalyst Pharmaceuticals Posts Q4 EPS Of $0.11
Catalyst Pharmaceuticals, Inc. is a commercial-stage, patient-centric biopharmaceutical company. The Company is focused on in-licensing, developing, and commercializing medicines for patients living with rare diseases. The Company is developing a pipeline of medicines for other rare diseases. The Company's product Firdapse Tablet, 10 mg, is used for the treatment of adults with Lambert-Eaton Myasthenic Syndrome (LEMS) patients (ages 17 and above) in the United States and Canada. Firdapse consists of the phosphate salt of amifampridine. It is developing a long-acting formulation of amifampridine phosphate. The Company's Firdapse is also developing clinical trials for the treatment of muscle-specific receptor tyrosine kinase-positive myasthenia gravis (MuSK-MG). Catalyst Pharmaceuticals Ireland, Ltd. is the subsidiary of the Company.
Biotechnology & Drugs
355 ALHAMBRA CIRCLE, SUITE 801
CORAL GABLES, FL
Patrick James McEnany
Chairman of the Board, President, Chief Executive Officer
Chief Financial Officer, Vice President, Treasurer
Steven R. Miller
Chief Operating Officer, Chief Scientific Officer
Brian D. Elsbernd
Chief Compliance Officer, Chief Legal Officer
Vice President, Head of Investor Relations
Price To Earnings (TTM)
Price To Sales (TTM)
Price To Book (MRQ)
Price To Cash Flow (TTM)
Total Debt To Equity (MRQ)
LT Debt To Equity (MRQ)
Return on Investment (TTM)
Return on Equity (TTM)
* DRUG SUPPLY REMAINS WELL-STOCKED WITH PATIENTS HAVING ACCESS TO UNINTERRUPTED SUPPLY OF FIRDAPSE (AMIFAMPRIDINE) 10MG
* CATALYST PHARMACEUTICALS CEO, ON IMPACT OF COVID-19, SAYS IMPLEMENTING VIRTUAL APPROACH TO GUARANTEE PATIENTS CONTINUAL ACCESS TO FIRDAPSE
* CATALYST PHARMACEUTICALS REPORTS FOURTH QUARTER AND YEAR-END 2019 FINANCIAL RESULTS AND PROVIDES CORPORATE UPDATE
Catalyst Pharmaceuticals Inc, which has come under fire for the high price tag on its rare disease drug, on Wednesday sued the U.S. Food and Drug Administration to challenge the recent approval of a lower-cost rival drug.
Catalyst Pharmaceuticals Inc said on Wednesday it has filed a lawsuit against the U.S. Food and Drug Administration, challenging the recent approval of Jacobus Pharmaceutical Co's drug, Ruzurgi, for a rare neuromuscular disease.
U.S. Senator Bernie Sanders this week urged regulators to allow pharmacies and manufacturers to resume distributing unbranded, lower-cost versions of a drug used to treat a rare neuromuscular disorder, according to a letter provided by his office to Reuters.
Catalyst Pharmaceuticals Inc, rebuked by U.S. Senator Bernie Sanders for its high drug prices, on Thursday defended its $375,000 treatment for a rare disease, saying the price was in line with similar products in the industry.
Catalyst Pharmaceuticals Inc, targeted by U.S. Senator Bernie Sanders for high drug prices, said on Thursday that prices of its treatment for a rare neurological disorder were "in line" with similar products in the industry.
Catalyst Pharmaceuticals Inc said on Monday that it expects its drug for a rare disease, which had long been available to patients for free, will cost more than $300,000 per year including rebates to insurers and other discounts.
Quote and financial data from Refinitiv. Fund performance data provided by Lipper. All quotes delayed a minimum of 15 minutes.